Stockscreener 앱 받기
4.95
0.40%
-0.02
전일 마감가:
$4.97
열려 있는:
$4.99
하루 거래량:
7,313
Relative Volume:
0.08
시가총액:
$46.64M
수익:
순이익/손실:
$-129.41M
주가수익비율:
-0.2055
EPS:
-24.0922
순현금흐름:
$-51.97M
1주 성능:
-4.81%
1개월 성능:
-15.96%
6개월 성능:
-42.58%
1년 성능:
+0.00%
1일 변동 폭
$4.88
$5.02
1주일 범위
$4.69
$5.75
52주 변동 폭
$2.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
명칭
Leonabio Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
4.95 | 46.64M | 0 | -129.41M | -51.97M | -24.09 |
VRTX
Vertex Pharmaceuticals Inc
|
525.63 | 133.23B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.80 | 83.27B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
205.71 | 82.12B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
879.53 | 55.31B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
375.74 | 42.50B | 5.76B | 514.49M | 1.10B | 4.4813 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-30 | 업그레이드 | Citizens | Mkt Perform → Mkt Outperform |
| 2026-05-27 | 개시 | Piper Sandler | Overweight |
| 2026-02-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Leonabio Inc 주식(LONA)의 최신 뉴스
LeonaBio Opens Warrant Exercise Window for New Capital - The Globe and Mail
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com South Africa
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com India
LeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.com - Investing.com Canada
LeonaBio (LONA) Stock Analysis Report | Financials & Insights - Benzinga España
LeonaBio to Participate in Cantor Global Healthcare Conference 2026 - Yahoo Finance
A drug developer's New York fireside chat is set for Sept. 11 - Stock Titan
Perceptive Advisors LLC Expands LeonaBio Inc (LONA) Stake in Str - GuruFocus
Sermonix Pharmaceuticals Discloses Investment at LeonaBio, Inc. with 36.9% Stake - TradingView
Prefunded warrants drive Sermonix-led LeonaBio (LONA) share shakeup - Stock Titan
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB) - The Globe and Mail
LeonaBio Reaches Key Phase 3 Enrollment Milestone - TipRanks
Perceptive's LeonaBio (NASDAQ: LONA) stake nears its ownership limit - Stock Titan
Anders Hove reports new passive stake in LeonaBio (LONA) - Stock Titan
LONA Maintained by Mizuho -- Price Target Lowered to $15.00 - GuruFocus
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Nigeria
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com South Africa
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com India
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Mizuho lowers LeonaBio stock price target on higher OpEx By Investing.com - Investing.com Canada
Mizuho lowers LeonaBio stock price target on higher OpEx - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), LeonaBio (LONA) - The Globe and Mail
LeonaBio Reports Narrower Quarter Loss as Trial Progresses - sekbernews.id
LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming Milestones - Pulse 2.0
LeonaBio (LONA) Market Close: Closes 3.19% Higher at $7.96 at the Close; Level Check: the Price Remains Bounded by the Supplied Support and Resistance under the Current SnapshotLow Volatility Picks - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Elicio Therapeutics (ELTX), EyePoint Pharmaceuticals (EYPT) and LeonaBio (LONA) - The Globe and Mail
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceWedge Breakout - vinanet.vn
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LONA Maintained by Citizens -- Price Target Lowered to $17.00 - GuruFocus
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances - Yahoo Finance
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Nigeria
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Australia
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio beats second quarter loss estimates By Investing.com - Investing.com Canada
LeonaBio price target lowered to $17 from $18 at Citizens - TipRanks
LeonaBio beats second quarter loss estimates - Investing.com
LeonaBio Inc (LONA) Q2 Results Highlight Challenges for Valuatio - GuruFocus
Citizens lowers LeonaBio stock price target to $17 on valuation By Investing.com - Investing.com Canada
LeonaBio Inc. (LONA) Climbs 2.84% to $8.19 as Biotech Buyers Target $8.60 ResistanceEarnings Quality Factor - dars.gov.et
LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade
LeonaBio Narrows Q2 Loss - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan
LeonaBio Q2 net loss widens on higher R&D spending - TradingView
LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative
LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - Kalkine
Leonabio Inc (LONA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Leonabio Inc 주식 (LONA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Litton Mark James | PRESIDENT and CEO |
Mar 04 '26 |
Sale |
5.37 |
5,156 |
27,688 |
57,926 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,720 |
9,236 |
15,887 |
| Mark James Litton | Officer |
Mar 04 '26 |
Proposed Sale |
5.36 |
5,156 |
27,662 |
0 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 04 '26 |
Sale |
5.37 |
1,359 |
7,298 |
25,178 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 04 '26 |
Sale |
5.37 |
1,328 |
7,131 |
18,376 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 04 '26 |
Sale |
5.37 |
906 |
4,865 |
15,851 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
7,418 |
0 |
17,607 |
| Renninger Robert | CHIEF FINANCIAL OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
3,900 |
0 |
16,757 |
| Worthington Mark | GENERAL COUNSEL and CCO |
Mar 03 '26 |
Option Exercise |
0.00 |
5,726 |
0 |
19,704 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Mar 03 '26 |
Option Exercise |
0.00 |
5,856 |
0 |
26,537 |
6.71%
0.00%
자본화:
|
볼륨(24시간):